Meng Li1,2, Miao-Miao Wang1,2, Xiu-Wei Guo1, Chao-Yong Wu2, Dao-Rui Li1, Xing Zhang2, Pei-Tong Zhang3. 1. Department of Oncology, Guang'anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, 100053, China. 2. Graduate School, Beijing University of Chinese Medicine, Beijing, 100029, China. 3. Department of Oncology, Guang'anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, 100053, China. drzhangpeitong@hotmail.com.
Abstract
OBJECTIVE: To assess the efficacy of Chinese medicine (CM) on patients with pancreatic cancer (PC) in a retrospective population-based study. METHODS: Between January 1, 2013, and August 30, 2016, according to whether received Western medicine treatment, the patients were included into either integrative medicine (IM) group or CM group. All enrolled patients were orally administrated with Gexia Zhuyu Decoction () or Liujun Ermu Decoction () by syndrome differentiation, twice a day, last for at least 2 months. The primary end point was overall survival (OS). RESULTS: A total of 174 patients with PC were enrolled in this study. In stage I/II, the median OS was 20.5 months in the IM group [95% confidence interval (CI), 12.499 to 28.501] and 11.17 months in the CM group (95% CI, 5.160 to 17.180, P=0.015). The 1- and 2-year survival rates for the two groups were 47.0%, 40.0% and 21.0%, 21.0%, respectively. In stage III/IV, median OS was 13.53 months (95% CI, 8.665 to 18.395) in the IM group versus 6.4 months (95% CI, 0.00 to 15.682) in the CM group, respectively (P=0.32). The 1- and 2-year survival rate for the IM and CM groups were 27.0%, 7.0% and 20.0%, 2.0%, respectively. CONCLUSIONS: Intervention of CM contributes to the different survival benefits for PC in different stages. Multimodality treatment might be a promising strategy for PC patients in early stage. While, in advanced stage, CM might be an alternative candidate for PC patients.
OBJECTIVE: To assess the efficacy of Chinese medicine (CM) on patients with pancreatic cancer (PC) in a retrospective population-based study. METHODS: Between January 1, 2013, and August 30, 2016, according to whether received Western medicine treatment, the patients were included into either integrative medicine (IM) group or CM group. All enrolled patients were orally administrated with Gexia Zhuyu Decoction () or Liujun Ermu Decoction () by syndrome differentiation, twice a day, last for at least 2 months. The primary end point was overall survival (OS). RESULTS: A total of 174 patients with PC were enrolled in this study. In stage I/II, the median OS was 20.5 months in the IM group [95% confidence interval (CI), 12.499 to 28.501] and 11.17 months in the CM group (95% CI, 5.160 to 17.180, P=0.015). The 1- and 2-year survival rates for the two groups were 47.0%, 40.0% and 21.0%, 21.0%, respectively. In stage III/IV, median OS was 13.53 months (95% CI, 8.665 to 18.395) in the IM group versus 6.4 months (95% CI, 0.00 to 15.682) in the CM group, respectively (P=0.32). The 1- and 2-year survival rate for the IM and CM groups were 27.0%, 7.0% and 20.0%, 2.0%, respectively. CONCLUSIONS: Intervention of CM contributes to the different survival benefits for PC in different stages. Multimodality treatment might be a promising strategy for PC patients in early stage. While, in advanced stage, CM might be an alternative candidate for PC patients.
Authors: Giuseppe Colucci; Roberto Labianca; Francesco Di Costanzo; Vittorio Gebbia; Giacomo Cartenì; Bruno Massidda; Elisa Dapretto; Luigi Manzione; Elena Piazza; Mirella Sannicolò; Marco Ciaparrone; Luigi Cavanna; Francesco Giuliani; Evaristo Maiello; Antonio Testa; Paolo Pederzoli; Massimo Falconi; Ciro Gallo; Massimo Di Maio; Francesco Perrone Journal: J Clin Oncol Date: 2010-03-01 Impact factor: 44.544
Authors: Yan Xu; Ai Guang Zhao; Zhao Yan Li; Gang Zhao; Yong Cai; Xiao Hong Zhu; Ni Da Cao; Jin Kun Yang; Jian Zheng; Yin Gu; Ying Ying Han; Ying Jie Zhu; Jin Zu Yang; Feng Gao; Qiang Wang Journal: Integr Cancer Ther Date: 2012-07-09 Impact factor: 3.279
Authors: Daniel D Von Hoff; Thomas Ervin; Francis P Arena; E Gabriela Chiorean; Jeffrey Infante; Malcolm Moore; Thomas Seay; Sergei A Tjulandin; Wen Wee Ma; Mansoor N Saleh; Marion Harris; Michele Reni; Scot Dowden; Daniel Laheru; Nathan Bahary; Ramesh K Ramanathan; Josep Tabernero; Manuel Hidalgo; David Goldstein; Eric Van Cutsem; Xinyu Wei; Jose Iglesias; Markus F Renschler Journal: N Engl J Med Date: 2013-10-16 Impact factor: 91.245